title: Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.
abstract: Human lumbar CSF patterns of Abeta peptides were analysed by urea-based beta-amyloid sodium dodecyl sulphate polyacrylamide gel electrophoresis with western immunoblot (Abeta-SDS-PAGE/immunoblot). A highly conserved pattern of carboxyterminally truncated Abeta1-37/38/39 was found in addition to Abeta1-40 and Abeta1-42. Remarkably, Abeta1-38 was present at a higher concentration than Abeta1-42, being the second prominent Abeta peptide species in CSF. Patients with Alzheimer's disease (AD, n = 12) and patients with chronic inflammatory CNS disease (CID, n = 10) were differentiated by unique CSF Abeta peptide patterns from patients with other neuropsychiatric diseases (OND, n = 37). This became evident only when we investigated the amount of Abeta peptides relative to their total Abeta peptide concentration (Abeta1-x%, fractional Abeta peptide pattern), which may reflect disease-specific gamma-secretase activities. Remarkably, patients with AD and CID shared elevated Abeta1-38% values, whereas otherwise the patterns were distinct, allowing separation of AD from CID or OND patients without overlap. The presence of one or two ApoE epsilon4 alleles resulted in an overall reduction of CSF Abeta peptides, which was pronounced for Abeta1-42. The severity of dementia was significantly correlated to the fractional Abeta peptide pattern but not to the absolute Abeta peptide concentrations.
authors.affiliation: Department of Psychiatry, University of Göttingen, Göttingen, Germany. jwiltfa@gwdg.de
authors.forename: J
authors.initials: J
authors.lastname: Wiltfang
authors.forename: H
authors.initials: H
authors.lastname: Esselmann
authors.forename: M
authors.initials: M
authors.lastname: Bibl
authors.forename: A
authors.initials: A
authors.lastname: Smirnov
authors.forename: M
authors.initials: M
authors.lastname: Otto
authors.forename: S
authors.initials: S
authors.lastname: Paul
authors.forename: B
authors.initials: B
authors.lastname: Schmidt
authors.forename: H-W
authors.initials: HW
authors.lastname: Klafki
authors.forename: M
authors.initials: M
authors.lastname: Maler
authors.forename: T
authors.initials: T
authors.lastname: Dyrks
authors.forename: M
authors.initials: M
authors.lastname: Bienert
authors.forename: M
authors.initials: M
authors.lastname: Beyermann
authors.forename: E
authors.initials: E
authors.lastname: Rüther
authors.forename: J
authors.initials: J
authors.lastname: Kornhuber
mesh_terms: D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000235:genetics; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid* / Q000737:chemistry / Q000378:metabolism; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics; D015415:Biomarkers / Q000032:analysis / Q000134:cerebrospinal fluid; D015153:Blotting, Western; D002490:Central Nervous System / Q000378:metabolism; D002493:Central Nervous System Diseases / Q000134:cerebrospinal fluid* / Q000175:diagnosis; D002908:Chronic Disease; D017124:Conserved Sequence; D004591:Electrophoresis, Polyacrylamide Gel; D004660:Encephalitis / Q000134:cerebrospinal fluid; D005260:Female; D006801:Humans; D015151:Immunoblotting; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid* / Q000737:chemistry; D011237:Predictive Value of Tests; D012720:Severity of Illness Index; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D016229:Amyloid beta-Peptides; D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D015415:Biomarkers; D010446:Peptide Fragments; C078639:amyloid beta-protein (1-38); C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42)